Evidence map›Paper›PMID 41097060›Full record

ArticleInternational journal of molecular sciences2025

Venous Thrombogenesis and Cervical Cancer: Plasma MicroRNAs as Prognostic Indicators of Tumor Behavior.

Mariana Teixeira Costa, Beatriz Vieira Neto, José Brito da Silva, Luísa Carvalho, Lurdes Salgado, Deolinda Pereira, Filomena Adega, Valéria Tavares, Rui Medeiros

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mariana Teixeira CostaMolecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Pathology and Laboratory Medicine Department/Clinical Pathology/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), 4200-072 Porto, Portugal.
Beatriz Vieira NetoMolecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Pathology and Laboratory Medicine Department/Clinical Pathology/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), 4200-072 Porto, Portugal.
José Brito da SilvaOncology Department, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal.ORCID 0000-0002-0181-5354
Luísa CarvalhoExternal Radiotherapy Department, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal.
Lurdes SalgadoExternal Radiotherapy Department, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal.
Deolinda PereiraOncology Department, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal.
Filomena AdegaCytoGenomics Lab, Department of Genetics and Biotechnology, University of Trás-os-Montes and Alto Douro, 5000-801 Vila Real, Portugal.
Valéria TavaresMolecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Pathology and Laboratory Medicine Department/Clinical Pathology/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), 4200-072 Porto, Portugal.ORCID 0000-0003-3680-7757
Rui MedeirosMolecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Pathology and Laboratory Medicine Department/Clinical Pathology/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), 4200-072 Porto, Portugal.ORCID 0000-0003-3010-8373

Funding

IPO Porto PI61-CI-IPOP-22-2015Liga Portuguesa Contra o Cancro LPCC-NRN2023-BVNLiga Portuguesa Contra o Cancro LPCC-NRN2025-VT
6 · The paper itself

Abstract

Cervical cancer (CC) is the fourth most common cancer among women globally, with venous thromboembolism (VTE) representing a life-threatening complication. Cancer-associated thrombosis (CAT) arises from tumor-driven activation of hemostasis, worsening prognosis. Recently, circulating microRNAs (miRNAs) have emerged as potential biomarkers for both CAT and cervical tumorigenesis. Thus, this study aimed to assess the implications of five miRNAs-miR-20a-5p, -23a-3p, -125b-5p, -145-5p, and -616-3p-in CC-related VTE context. These miRNAs were quantified by RT-qPCR in plasma from 69 CC patients before treatment. Briefly, VTE occurred in nine patients, decreasing overall survival (OS) [log-rank test,

Indexed as

Biomarkers, TumorCarcinoma, Squamous CellCirculating MicroRNAUterine Cervical NeoplasmsVenous ThromboembolismCarcinogenesisCervix UteriFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMiddle AgedPrognosisRetrospective StudiesBiomarkers, TumorCirculating MicroRNAbiomarkerscancer-associated thrombosiscervical cancermicroRNAsprognosisvenous thromboembolism

Identifiers

PMID41097060
PMCPMC12524682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.